iShares US Pharmaceuticals ETF
91 hedge funds and large institutions have $104M invested in iShares US Pharmaceuticals ETF in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 34 reducing their positions, and 18 closing their positions.
227% more call options, than puts
Call options by funds: $755K | Put options by funds: $231K
7% more capital invested
Capital invested by funds: $96.6M → $104M (+$6.98M)
0.5% more ownership
Funds ownership: 80.72% → 81.21% (+0.5%)
5% less funds holding
Funds holding: 96 → 91 (-5)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
47% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 34
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.81M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.37M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.48M |
| 4 |
Jane Street
New York
|
+$1.87M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
-$7.84M |
| 2 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$1.55M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.25M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$1.11M |
| 5 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
-$1.04M |
IHE Hedge Fund Activity: Q1 2019 in Review
91 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2019, worth a combined $104M — up 7.2% from $96.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of IHE and 14 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 18 added.
The largest buyer was Citadel Advisors, adding an estimated $5.81M. The largest seller was Colony Group, exiting entirely with an estimated $7.84M sold.
- 91 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2019, down from 96 in Q4 2018.
- Funds reported $104M of iShares US Pharmaceuticals ETF stock for Q1 2019, up 7.2% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2019 and 18 closed out, a net change of -4 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2019 was Citadel Advisors, an estimated $5.81M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2019 was Colony Group, an estimated $7.84M sold.
Based on aggregated 13F filings for Q1 2019.